Progenteq is developing a novel cartiledge replacement therapy that has the potential to revolutionise the treatment of acute knee injuries. The company was founded in 2010 on the work of Professor Charlie Archer's research group at Cardiff University's School of Biosciences. Professor Archer is Leader of the Connective Tissue Biology Group, recognised for excellence in tissue engineering and repair research.
|
As at 31 Dec 2012 |
IP Group holding |
|
12.0% |
|
Holding represents undiluted beneficial equity interest excluding debt